AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 81 min read$IRD

Gagnon Robert E. sold $127K of IRD

Gagnon Robert E. (Chief Financial Officer) sold 28,000 shares of Opus Genetics, Inc. (IRD) at $4.54 ($0.13M total) on 2026-09-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Gagnon Robert E.
Published Sep 8, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 8:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$IRD
Neutral
high confidence
Mentioned
$IRD
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IRDNeutralLow
01

Why it matters

The CFO's sale is modest and pre‑arranged, offering limited insight into company fundamentals.

02

Market read

Routine insider sale with minimal market impact.

03

What to watch

Potential upcoming corporate actions or earnings that may affect insider holdings.

Relevance 3/10Novelty 3/10Timing: filing Sep 8, sale dated Sep 3

Background

Form 4 filings disclose insider trades; investors monitor them for signals.

Company-level read

Ticker impact

$IRDNeutralHigh confidence
Context

CFO Robert Gagnon sold 28,000 shares of Opus Genetics (IRD) for $127,212 via a 10b5‑1 plan.

Expected impact

No material impact on IRD stock price.

Evidence & confidence

The sale size is small relative to total shares outstanding and follows a pre‑arranged plan.

Market effects

Sector

None; isolated insider transaction.

Regional

None

Global

None

Counterpoint

What could challenge this read

Even small insider sales can signal concerns, but the 10b5‑1 plan suggests routine execution.

Key entities

  • Company
    Opus Genetics, Inc.

    Biotech firm listed on NASDAQ under ticker IRD.

  • Individual
    Robert E. Gagnon

    Chief Financial Officer of Opus Genetics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

IRD insider trading history →

Related articles

SEP 16
$IRDMedAI 8/10

Opus Genetics (IRD) Reports Five Early BIRD-1 Responses. Is Phase 3 Planning Justified?

Opus Genetics (NASDAQ: IRD) reported that all five participants in its BIRD-1 trial showed clinically meaningful improvements in visual function. The Phase 1/2 trial included patients with Best vitelliform macular dystrophy and autosomal recessive bestrophinopathy, with no serious adverse events. The company is considering Phase 3 planning, with FDA alignment on potential endpoints. Higher-dose cohort dosing is expected to finish in Q4 2026, with topline results in Q2 2027.

insidermonkey.com2 min
SEP 11
$IRDMedAI 8/10

Opus Genetics, Inc. (IRD): OPGx-BEST1 Gene Therapy Phase 1/2 Study Low Dose Cohort 1 3-month Results September 9, 2026

Opus Genetics, Inc. (IRD) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 OPGx-BEST1 Gene Therapy Phase 1/2 Study Low Dose Cohort 1 3-month Results September 9, 2026 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looki

SEC EDGAR 8-K1 min